BIOPROMIC
Information about cookies
Biopromic website uses cookies. According to the Electronic Communications Act, anyone visiting a website with cookies must be given access to information that the site contains cookies, as well as the purpose/use of these.
As a user you should also be able to agree that cookies are stored on your computer, which may be by settings in the browser you are using.
What are cookies?
Cookies are small text files consisting of letters and numbers. These are sent from our website or our partners servers and stored on your device as shown below. We use different cookies:
- Session cookies are a temporary cookie that ends when you close your browser or an app.
- Permanent cookies remain on your computer until you delete them or they expire.
- First-party cookies are cookies set by the website you visit.
- Third-party cookies are cookies set by a third-party page.
Why do we use cookies?
- For web analytics. For example, to get information about how visitors interact with the site.
- By using cookies we can customize advertising according to your behavior and show relevant products/services to the right person.
- To improve your experience. For example, to create personalized offers, remember what’s in your shopping cart and enable different services and features to work as they should.
The cookies we use improve the services/products we offer you. Some of our services actually need cookies to work properly, while others are simply available to make our services more manageable or flexible for you or your business.
Necessary cookies are absolutely necessary to provide our basic features & services, such as logins, remembering a shopping cart or a customer portal. Our services would not work without these cookies.
Analysis cookies provide comprehensive analytical information regarding your use of our services.
Function cookies allow you to save settings such as language/browser settings, or if we will auto complete your information, eg form/checkout or not. Without these cookies, we would not be able to tailor our services to your requirements. These cookies are necessary, as it is essential for our services that your experience with us should be as good and smooth as possible.
Security cookies make our services and your data safe and secure, as they help us detect fraud/hacking attempts and protect your data properly. Since this is an incredibly important part of our services, these cookies are clearly necessary.
Third-party cookies
Biopromic are working on several acts that put their third-party cookies on our site. Information collected through these cookies can be shared with other companies but also used for other purposes.
This is controlled and controlled by the respective supplier who delivers them.
Google analytics/search console/Tag-manager.
Biopromic uses this tool for tracking & analysis of our visitors. Google means that users remain anonymous and no identifiable information is sent or shared.
Hotjar
Hotjar analyzes how users navigate across the pages of the site with the mouse pointer. Recording of the visitor’s pointer takes place in order to analyze how visitors interact with the webpage. The user’s data is anonymized and there is no unique identifier of visitors.
Biopromic allows cookies from Facebook as third-parties. When people who are logged in to Facebook visit a website using Facebook’s advertising solutions, the browser sends certain information to Facebook, such as the URL of the site. The purpose of using this is to improve targeted marketing on Facebook through a survey of visitor interaction with our website.
How do I say no to cookies?
If you do not accept cookies, you can configure your browser so that cookie files are not downloaded to your computer. This will close all cookies. Temporary cookies are necessary to navigate our website; the website will not work unless temporary cookies are accepted.
If you do not want data about you to be collected, you can block cookies from third party-cookies in your web browser.
Biopromic awarded Medtech 4 Health grant from Vinnova
/0 Comments/in Press release /by paulWe are hapy to anounce that Biopromic, together with Volkan Ozenci from Karolinska Institute and Simon Atlin from Örebro Univeristy has been awarded a Medtech 4 health grant for development and evaluation of sample treatment platform for infectious disease immunoassaysIn this Project we aim to validate the SpeClean technology as a new standard treatment of samples. This would allow many more infectious disease diagnostics to be performed at primary health care centers or at the patient’s bedside.
SpeClean is our new sample preparation technology directed at improving the performance of currently available immunoassays for infectious diseases. The sample treatment aims to remove inhibitory substances from biological samples like urine, saliva or blood, which results in a significant improvement in the sensitivity of the test and reduces unspecific background. In turn, this allows for simpler and more robust tests to be utilized in place of traditional assays.
Project is a cooperation of Biopromic AB, Karolinska Institute and Örebro University Hospital and will last for 18 months starting February 2019, with Vinnova support of over 1,4mln SEK.
Biopromic in collaboration with Asahi-Kasei awarded a GHIT grant for development of LFA platform
/0 Comments/in Press release /by paulBiopromic nominated to European Health Catapult
/0 Comments/in Press release /by paulGlobal Good and Biopromic Partner to Co-Develop Low-Cost Diagnostic to Detect Tuberculosis
/in Press release /by paulBiopromic AB announced a technology co-development and license agreement with The Global Good Fund, managed by Intellectual Ventures, to develop a rapid, low-cost and high-sensitivity diagnostic test for the detection of tuberculosis (TB), one of the leading causes of death worldwide. The partnership will combine Global Good’s assay platform with Biopromic’s proprietary technologies in sample preparation and high-sensitivity antibodies to improve the accessibility of accurate TB testing in low- and middle-income countries
Despite significant progress made in recent decades, TB still kills 1.8 million people and another 10.4 million develop the disease every year – the majority of whom live in low-income countries. The disease, which spreads from person to person through coughing, sneezing and even talking, is the leading killer of people living with HIV.
The most commonly accessible diagnostic tool, microscopy, may detect only half of all TB cases at best. Two other tests — nucleic acid amplification and conventional growth detection — are accurate, but their use in low-resource settings is limited by high cost, the need for specialized laboratory equipment, turnaround time, and the complexity of handling and incubating biological samples and interpreting results.
The test developed by Biopromic and Global Good will be similar in format to a home pregnancy test and use a patient’s urine or blood sample to detect bacteria associated with the disease.
“In order to identify and treat all TB patients and stop the spread of the disease, frontline health workers need a simple, but highly accurate diagnostic test that can be used close to where patients live,” said David Bell, Director of Global Health Technologies supporting Global Good, a collaboration between Intellectual Ventures and Bill Gates.“If we can develop such a low-cost tool, this could transform the fight against TB,” added Bell.
“Biopromic’s partnership with Global Good will significantly accelerate our efforts to bring a point-of-care TB diagnostic to the market, and ensure that TB testing is accessible to those who need it the most,” said Lech Ignatowicz, CEO of Biopromic.
About Global Good
Global Good is a collaboration between Intellectual Ventures and Bill Gates to invent technology that improves life in low- and middle-income countries. With support from a coalition of NGO, government and business partners, we conceive, develop and deploy inventions for the poorest parts of the world. Global Good combines Intellectual Ventures’ unique invention prowess with the expertise of leading humanitarian organizations, forward-looking governments, and commercial partners that share our vision. Together, we invent, develop, and deploy commercially-viable technologies that improve life in developing countries. www.globalgood.com
About Biopromic
Biopromic is working to change the future of rapid, point-of-care diagnostics for the detection of infectious diseases. A spectrum of Biopromic’s proprietary technologies allows for the development of simple-to-use and affordable tests for clinical and veterinary settings. Biopromic specializes in the production of ultra-sensitive monoclonal antibodies targeted primarily against carbohydrate antigens derived from bacteria and viruses. Biopromic also produces a wide range of bacterial antigens and their analogs. Biopromic is a privately held company established in 2006 in Poland. In 2017, Biopromic opened its new R&D facility at Karolinska Institutet Science Park in Stockholm, Sweden. www.biopromic.com
Extensive information on tuberculosis (TB) epidemic and its devastating impact on global health can be found at: WHO Global Tuberculosis Rapport 2016